| 11.814 0.274 (2.37%) | 10-15 12:18 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 17.23 | 1-year : | 20.18 |
| Resists | First : | 14.75 | Second : | 17.28 |
| Pivot price | 11.72  |
|||
| Supports | First : | 10.68 | Second : | 8.88 |
| MAs | MA(5) : | 11.6  |
MA(20) : | 12.1 |
| MA(100) : | 13.24 |
MA(250) : | 11.66 |
|
| MACD | MACD : | -0.6 |
Signal : | -0.6 |
| %K %D | K(14,3) : | 38.1 |
D(3) : | 32.2 |
| RSI | RSI(14): 43.8 |
|||
| 52-week | High : | 17.28 | Low : | 7.3 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ KALV ] has closed below upper band by 42.9%. Bollinger Bands are 52% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 11.79 - 11.84 | 11.84 - 11.9 |
| Low: | 11.08 - 11.14 | 11.14 - 11.2 |
| Close: | 11.44 - 11.54 | 11.54 - 11.63 |
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; KVD824, an oral product candidate for the treatment of HAE; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.
Tue, 07 Oct 2025
KalVista: Prophylaxis Is Shrinking The Acute HAE TAM (NASDAQ:KALV) - Seeking Alpha
Mon, 06 Oct 2025
100,000-share options each: KalVista names Bilal Arif COO, Linea Aspesi Chief People Officer - Stock Titan
Fri, 03 Oct 2025
KalVista Pharmaceuticals Appoints Bethany Sensenig to Board - The Globe and Mail
Wed, 24 Sep 2025
KalVista Pharmaceuticals Announces Proposed Offering of $110.0 Million of Convertible Senior Notes - Business Wire
Fri, 12 Sep 2025
KalVista Pharmaceuticals Inc (KALV) Q1 2026 Earnings Call Highlights: EKTERLY Launch Drives ... - Yahoo Finance
Thu, 11 Sep 2025
KalVista Pharmaceuticals, Inc. (KALV) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 51 (M) |
| Held by Insiders | 2.831e+007 (%) |
| Held by Institutions | 1.2 (%) |
| Shares Short | 10,560 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.0182e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -4 % |
| Return on Assets (ttm) | 138 % |
| Return on Equity (ttm) | -61 % |
| Qtrly Rev. Growth | 1.43e+006 % |
| Gross Profit (p.s.) | -1.43 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.72 |
| Qtrly Earnings Growth | -4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -167 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.2 |
| Dividend | 0 |
| Forward Dividend | 1.27e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|